Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The muscle-type alpha-1-beta-1-gamma-delta nicotinic acetylcholine receptor is a pentameric ligand-gated ion channel that serves as the primary mediator of neuromuscular transmission in the developing fetus and in denervated adult muscle (Wikipedia, 2024; PMC, 2009). It is composed of two alpha-1 subunits and one each of the beta-1, gamma, and delta subunits, distinguishing it from the adult isoform which contains an epsilon subunit instead of the gamma subunit (Wikipedia, 2024; PMC, 2011). Upon binding of the neurotransmitter acetylcholine to its extracellular sites, the receptor undergoes a conformational change that opens a central pore, allowing the influx of cations such as sodium and calcium, which leads to muscle fiber depolarization and subsequent contraction (ResearchGate, 2007; PubMed, 1994). This receptor is a critical target in the pathogenesis of myasthenia gravis, where autoantibodies—some specifically targeting the fetal gamma subunit—cause receptor loss and impaired synaptic signaling (PMC, 2012; MDPI, 2023). Pharmacologically, it is the site of action for neuromuscular blocking agents used in clinical anesthesia, including competitive antagonists like pancuronium and depolarizing agonists like succinylcholine, as well as various potent neurotoxins from snake and cone snail venoms (PubMed, 2002; MDPI, 2024). Understanding the distinction between the fetal and adult forms is essential for diagnosing neonatal myasthenia and developing subtype-specific therapeutic interventions (Frontiers, 2025; eMedicine, 2025).
Agonist binding to the extracellular domain (specifically at the alpha-gamma and alpha-delta subunit interfaces) induces a conformational change that opens a central cation-selective pore. This allows the influx of sodium and calcium ions and the efflux of potassium ions, leading to membrane depolarization of the motor endplate and triggering muscle contraction.
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Muscle-type alpha-1-beta-1-gamma-delta nicotinic acetylcholine receptor (fetal nAChR).